{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:07:00Z","timestamp":1780517220916,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cpet.2026.03.006","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:49:02Z","timestamp":1777348142000},"page":"353-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["State-of-the-Art Theranostics of Thyroid Cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"Michael C.","family":"Kreissl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Hescheler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pfestroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Di Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Eilsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cpet.2026.03.006_bib1","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1172\/JCI60047","article-title":"Mechanisms of thyroid hormone action","volume":"122","author":"Brent","year":"2012","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.cpet.2026.03.006_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/thy.1997.7.163","article-title":"Radioiodine and the treatment of hyperthyroidism: the early history","volume":"7","author":"Sawin","year":"1997","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.cpet.2026.03.006_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0001-2998(96)80020-1","article-title":"Radioiodine and thyroid disease: the beginning","volume":"26","author":"Becker","year":"1996","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.cpet.2026.03.006_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jama.1946.02870190005002","article-title":"Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism","volume":"131","author":"Hertz","year":"1946","journal-title":"J Am Med Assoc"},{"issue":"4","key":"10.1016\/j.cpet.2026.03.006_bib5","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.3892\/mmr.2014.3096","article-title":"Iodine-131 induces apoptosis in HTori-3 human thyrocyte cell line and G2\/M phase arrest in a p53-independent pathway","volume":"11","author":"Zhang","year":"2015","journal-title":"Mol Med Rep"},{"issue":"2","key":"10.1016\/j.cpet.2026.03.006_bib6","first-page":"120","article-title":"Iodine-131 for therapy of thyroid diseases. Physical and biological basis","volume":"15","author":"Wyszomirska","year":"2012","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"10.1016\/j.cpet.2026.03.006_bib7","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Schilddr\u00fcsenkarzinom, Langversion 1.0, 2025, AWMF-Registernummer: 031-056OL, Available at: https:\/\/www.leitlinienprogramm- (Accessed 30 December 2025)."},{"issue":"5","key":"10.1016\/j.cpet.2026.03.006_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00259-012-2331-5","article-title":"124I PET\/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy 131I SPECT\/CT","volume":"40","author":"de Pont","year":"2013","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"9","key":"10.1016\/j.cpet.2026.03.006_bib9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2967\/jnumed.115.169649","article-title":"High level of agreement between pretherapeutic 124I PET and intratherapeutic 131I imaging in detecting iodine-positive thyroid cancer metastases","volume":"57","author":"Ruhlmann","year":"2016","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.cpet.2026.03.006_bib10","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1210\/jc.2011-0494","article-title":"Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer","volume":"96","author":"Klubo-Gwiezdzinska","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.cpet.2026.03.006_bib11","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s00259-010-1565-3","article-title":"Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET\/CT dosimetric comparisons","volume":"37","author":"Freudenberg","year":"2010","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"19","key":"10.1016\/j.cpet.2026.03.006_bib12","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1158\/1078-0432.CCR-22-0437","article-title":"Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK inhibition (ERRITI): a single-center prospective two-arm study","volume":"28","author":"Weber","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.cpet.2026.03.006_bib13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/RLU.0000000000001977","article-title":"Initial clinical investigation of [18F]Tetrafluoroborate PET\/CT in comparison to [124I]Iodine PET\/CT for imaging thyroid cancer","volume":"43","author":"Samnick","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2026.03.006_bib14","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s00259-020-04727-9","article-title":"Incremental diagnostic value of [(18)F]tetrafluoroborate PET-CT compared to [(131)I]iodine scintigraphy in recurrent differentiated thyroid cancer","volume":"47","author":"Dittmann","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"24","key":"10.1016\/j.cpet.2026.03.006_bib15","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1080\/14796694.2025.2560294","article-title":"[(18)F]Tetrafluoroborate PET\/CT for detecting differentiated thyroid cancer: phase-II study protocol","volume":"21","author":"Coerts","year":"2025","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2026.03.006_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-0029-1243636","article-title":"Somatostatin receptor subtype expression in human thyroid tumours","volume":"42","author":"Klagge","year":"2010","journal-title":"Horm Metab Res"},{"issue":"7","key":"10.1016\/j.cpet.2026.03.006_bib17","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s00259-014-2723-9","article-title":"Prospective evaluation of (68)Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative (131)I-whole body scan: comparison with (18)F-FDG PET-CT","volume":"41","author":"Kundu","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"10","key":"10.1016\/j.cpet.2026.03.006_bib18","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.2967\/jnumed.115.171942","article-title":"68Ga-DOTATOC PET\/CT in patients with Iodine- and 18F-FDG-Negative differentiated thyroid carcinoma and elevated serum thyroglobulin","volume":"57","author":"Binse","year":"2016","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"10.1016\/j.cpet.2026.03.006_bib19","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy","volume":"10","author":"Krenning","year":"1999","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.cpet.2026.03.006_bib20","first-page":"107s","article-title":"Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma","volume":"46","author":"Teunissen","year":"2005","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2026.03.006_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/RLU.0000000000000429","volume":"39","author":"Jois","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2026.03.006_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4103\/wjnm.WJNM_21_19","article-title":"Clinical efficacy of (177)Lu-DOTATATE peptide receptor radionuclide therapy in thyroglobulin-elevated negative iodine scintigraphy: a \u201cnot-so-promising\u201d result compared to GEP-NETs","volume":"19","author":"Basu","year":"2020","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.cpet.2026.03.006_bib23","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s11307-025-02053-w","article-title":"Peptide receptor radionuclide therapy with Lu-177-DOTATATE and monitoring with somatostatin receptor PET\/CT in patients with advanced differentiated thyroid carcinoma","volume":"27","author":"Kunte","year":"2025","journal-title":"Mol Imag Biol"},{"issue":"11","key":"10.1016\/j.cpet.2026.03.006_bib24","doi-asserted-by":"crossref","first-page":"9867","DOI":"10.18632\/oncotarget.23984","article-title":"Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid","volume":"9","author":"Heitk\u00f6tter","year":"2018","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.cpet.2026.03.006_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225688","article-title":"Prostate-specific membrane antigen in Anaplastic and poorly differentiated thyroid Cancer-A new diagnostic and therapeutic target?","volume":"13","author":"W\u00e4chter","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cpet.2026.03.006_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13550-020-0610-x","article-title":"(68)Ga-PSMA PET\/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with (177)Lu-PSMA-617","volume":"10","author":"de Vries","year":"2020","journal-title":"EJNMMI Res"},{"issue":"11","key":"10.1016\/j.cpet.2026.03.006_bib27","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/MNM.0000000000002036","article-title":"Head-to-head comparison of [ 18 F] fluorodeoxyglucose PET\/CT and [ 68 Ga]Ga-prostate specific membrane antigen-11 PET\/CT in radioactive iodine refractory differentiated thyroid cancer","volume":"46","author":"Kibar","year":"2025","journal-title":"Nucl Med Commun"},{"issue":"3","key":"10.1016\/j.cpet.2026.03.006_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13030564","article-title":"Potential role of PSMA-targeted PET in thyroid malignant disease: a systematic review","volume":"13","author":"Rizzo","year":"2023","journal-title":"Diagnostics"},{"issue":"6","key":"10.1016\/j.cpet.2026.03.006_bib29","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2026.03.006_bib30","first-page":"2","article-title":"Head-to-head comparison of (18)F-FDG versus (18)F-FAPI-74 PET in radioactive-iodine refractory differentiated thyroid cancer patients","volume":"28","author":"Hadjitheodorou","year":"2025","journal-title":"Hellenic J Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2026.03.006_bib31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00259-023-06404-z","article-title":"Head-to-head comparison of [(68)Ga]Ga-DOTA.SA.FAPi with [(18)F]F-FDG PET\/CT in radioiodine-resistant follicular-cell derived thyroid cancers","volume":"51","author":"Ballal","year":"2023","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.cpet.2026.03.006_bib32","first-page":"65","article-title":"Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study","volume":"32","author":"Ballal","year":"2022","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.cpet.2026.03.006_bib33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1089\/thy.2024.0229","article-title":"Long-term outcomes in radioiodine-resistant follicular cell-derived thyroid cancers treated with [(177)Lu]Lu-DOTAGA.FAPi dimer therapy","volume":"35","author":"Ballal","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.cpet.2026.03.006_bib34","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2147\/OTT.S67393","article-title":"Nanotetrac targets integrin \u03b1v\u03b23 on tumor cells to disorder cell defense pathways and block angiogenesis","volume":"7","author":"Davis","year":"2014","journal-title":"OncoTargets Ther"},{"issue":"Supplement_1","key":"10.1016\/j.cpet.2026.03.006_bib35","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf149.2444","article-title":"SAT-301 thyroid Hormone- integrin \u03b1v\u03b23 signaling in thyroid cancer","volume":"9","author":"Abaandou","year":"2025","journal-title":"J Endocr Soc"},{"issue":"1","key":"10.1016\/j.cpet.2026.03.006_bib36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40644-022-00511-0","article-title":"Evaluation of integrin \u03b1(v)\u03b2(3)-targeted imaging for predicting disease progression in patients with high-risk differentiated thyroid cancer (using (99m)Tc-3PRGD(2))","volume":"22","author":"Liang","year":"2022","journal-title":"Cancer Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2026.03.006_bib37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41598-017-19036-9","article-title":"Clinical value of (99m)Tc-3PRGD2 SPECT\/CT in differentiated thyroid carcinoma with negative (131)I whole-body scan and elevated thyroglobulin level","volume":"8","author":"Gao","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.cpet.2026.03.006_bib38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/thy.2019.0450","volume":"30","author":"Parihar","year":"2020","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.cpet.2026.03.006_bib39","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1007\/s00259-018-4036-x","article-title":"Novel use of (177)Lu-DOTA-RGD(2) in treatment of (68)Ga-DOTA-RGD(2)-avid lesions in papillary thyroid cancer with TENIS","volume":"45","author":"Parihar","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"5","key":"10.1016\/j.cpet.2026.03.006_bib40","doi-asserted-by":"crossref","first-page":"e0156044","DOI":"10.1371\/journal.pone.0156044","article-title":"Overexpression of L-Type amino acid transporter 1 (LAT1) and 2 (LAT2): novel markers of neuroendocrine tumors","volume":"11","author":"Barollo","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cpet.2026.03.006_bib41","first-page":"2417","article-title":"Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma","volume":"83","author":"Mato","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"22 Pt 1","key":"10.1016\/j.cpet.2026.03.006_bib42","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-07-0935","article-title":"Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial","volume":"13","author":"Iten","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cpet.2026.03.006_bib43","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12885-019-5540-5","article-title":"Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls","volume":"19","author":"Beukhof","year":"2019","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.cpet.2026.03.006_bib44","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1097\/RLU.0000000000005558","article-title":"Head-to-Head comparison of 68Ga-FAPI-04 and 68Ga-DOTA-TATE PET\/CT in recurrent medullary thyroid cancer","volume":"50","author":"Isik","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2026.03.006_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061889","article-title":"Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics","volume":"15","author":"Martin","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.cpet.2026.03.006_bib46","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1097\/RLU.0000000000005723","article-title":"Combination therapy with 177 Lu-FAPI-2286 and tyrosine kinase inhibitor: a novel approach for treating metastatic medullary thyroid carcinoma","volume":"50","author":"Raeisi","year":"2025","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2026.03.006_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1627500","article-title":"[(68)Ga]Ga-PSMA-11 PET\/CT in medullary thyroid carcinoma: comparison with [(18)F]FDG PET\/CT and immunohistochemical analysis","volume":"16","author":"Zajkowska","year":"2025","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859826000325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859826000325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:40:24Z","timestamp":1780515624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859826000325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1556859826000325"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2026.03.006","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State-of-the-Art Theranostics of Thyroid Cancer","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2026.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}